- Enlivex Therapeutics (ENLV, Financial) has completed patient enrollment for the Phase II stage of its Allocetra™ clinical trial.
- The trial focuses on treating moderate to severe knee osteoarthritis with promising initial Phase I results.
- Topline data from the Phase II stage is expected by August 2025.
Enlivex Therapeutics Ltd. (ENLV), a clinical-stage company specializing in macrophage reprogramming immunotherapy, announced the completion of patient enrollment in the Phase II stage of its Phase I/II clinical trial. The trial evaluates Allocetra™ as a treatment for moderate to severe knee osteoarthritis.
The randomized, controlled, and blinded study has successfully enrolled 133 patients. This advancement follows promising initial efficacy data from Phase I, and the company remains on track to achieve a 3-month topline data readout by August 2025.
CEO Oren Hershkovitz expressed confidence in Allocetra™, anticipating its potential to transform osteoarthritis treatment by effectively relieving joint pain and improving joint function. Enlivex is eager to analyze the upcoming data to further validate Allocetra™'s efficacy and safety profile.
Osteoarthritis is a prevalent condition affecting more than 32.5 million Americans and over 300 million people globally. Given its impact, there is an urgent need for effective treatments, especially since no current FDA or EMA approved medications can halt or reverse joint structural damage. Allocetra™ represents a promising frontier in addressing this unmet medical need.
